Christof C Smith
Overview
Explore the profile of Christof C Smith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1407
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ricketts C, de Cubas A, Fan H, Smith C, Lang M, Reznik E, et al.
Cell Rep
. 2024 Apr;
43(4):113063.
PMID: 38578829
No abstract available.
2.
Vensko S, Olsen K, Bortone D, Smith C, Chai S, Beckabir W, et al.
Bioinformatics
. 2023 May;
39(6).
PMID: 37184881
Motivation: Elimination of cancer cells by T cells is a critical mechanism of anti-tumor immunity and cancer immunotherapy response. T cells recognize cancer cells by engagement of T cell receptors...
3.
Chai S, Smith C, Kochar T, Hunsucker S, Beck W, Olsen K, et al.
Bioinform Adv
. 2022 Jun;
2(1):vbac032.
PMID: 35669345
Motivation: Splice variant neoantigens are a potential source of tumor-specific antigen (TSA) that are shared between patients in a variety of cancers, including acute myeloid leukemia. Current tools for genomic...
4.
Nishijima T, Kardos J, Chai S, Smith C, Bortone D, Selitsky S, et al.
JCO Precis Oncol
. 2022 Feb;
1:1-10.
PMID: 35172495
Purpose: Claudin-low molecular subtypes have been identified in breast and bladder cancers and are characterized by low expression of claudins, enrichment for epithelial-to-mesenchymal transition (EMT), and tumor-initiating cell (TIC) features....
5.
Truong A, Zhou M, Krishnan B, Utsumi T, Manocha U, Stewart K, et al.
J Clin Invest
. 2021 Aug;
131(16).
PMID: 34396985
Although immune-checkpoint inhibitors (ICIs) have been a remarkable advancement in bladder cancer treatment, the response rate to single-agent ICIs remains suboptimal. There has been substantial interest in the use of...
6.
Smith C, Olsen K, Gentry K, Sambade M, Beck W, Garness J, et al.
Genome Med
. 2021 Jun;
13(1):101.
PMID: 34127050
Background: Early in the pandemic, we designed a SARS-CoV-2 peptide vaccine containing epitope regions optimized for concurrent B cell, CD4 T cell, and CD8 T cell stimulation. The rationale for...
7.
Shiuan E, Reddy A, Dudzinski S, Lim A, Sugiura A, Hongo R, et al.
Cancers (Basel)
. 2021 Apr;
13(6.
PMID: 33806963
Predicting response to ICI therapy among patients with renal cell carcinoma (RCC) has been uniquely challenging. We analyzed patient characteristics and clinical correlates from a retrospective single-site cohort of advanced...
8.
Beckermann K, Hongo R, Ye X, Young K, Carbonell K, Healey D, et al.
JCI Insight
. 2020 Aug;
5(16.
PMID: 32814710
Metabolic reprogramming dictates the fate and function of stimulated T cells, yet these pathways can be suppressed in T cells in tumor microenvironments. We previously showed that glycolytic and mitochondrial...
9.
Smith C, Entwistle S, Willis C, Vensko S, Beck W, Garness J, et al.
bioRxiv
. 2020 Jun;
PMID: 32577654
There is an urgent need for a vaccine with efficacy against SARS-CoV-2. We hypothesize that peptide vaccines containing epitope regions optimized for concurrent B cell, CD4 T cell, and CD8...
10.
Landoni E, Smith C, Fuca G, Chen Y, Sun C, Vincent B, et al.
Cancer Immunol Res
. 2019 Nov;
8(1):57-69.
PMID: 31719055
T-cell receptor (TCR) gene transfer redirects T cells to target intracellular antigens. However, the potential autoreactivity generated by TCR mispairing and occurrence of graft-versus-host disease in the allogenic setting due...